These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3474080)

  • 1. 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
    Bruzzone M; Chiara S; Falcone A; Graziani G; Conte PF; Rosso R
    Chemioterapia; 1987 Apr; 6(2):137-9. PubMed ID: 3474080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
    Bastholt L; Dalmark M
    Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    ; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.
    Hakes TB; Daghestani AN; Dougherty JB; Weiselberg L; Raymond V
    Cancer Treat Rep; 1985 May; 69(5):559-60. PubMed ID: 3859369
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer.
    Havsteen H; Bertelsen K; Gadeberg CC; Jacobsen A; Kamby C; Sandberg E; Sengeløv L
    Gynecol Oncol; 1996 Nov; 63(2):210-5. PubMed ID: 8910629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of 4-demethoxydaunorubicin toxicity (IMI 30). Preliminary data].
    Nobile MT; Pronzato P; Campora E; Ardizzoni A; Grimaldi A; Lionetto R; Repetto L; Rosso R
    G Ital Chemioter; 1985; 32(1):29-30. PubMed ID: 3913619
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
    Martoni A; Pacciarini MA; Pannuti F
    Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
    Lopez M; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N; Lazzaro B
    Cancer Treat Rep; 1986 Jul; 70(7):911-2. PubMed ID: 3459575
    [No Abstract]   [Full Text] [Related]  

  • 11. Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors.
    Bertelli G; Amoroso D; Pronzato P; Rosso R
    Anticancer Res; 1988; 8(4):645-6. PubMed ID: 3178154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
    Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
    Invest New Drugs; 1986; 4(3):275-8. PubMed ID: 3469171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
    Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of idarubicin in advanced endometrial carcinoma.
    Hakes TB; Raymond V
    Cancer Treat Rep; 1987 May; 71(5):535-6. PubMed ID: 3471330
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
    Fleming GF; Waggoner SE; Rotmensch J; Skoog LA; Langhauser C
    Gynecol Oncol; 1997 Apr; 65(1):42-5. PubMed ID: 9103389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin in advanced breast cancer: a phase II study.
    Lionetto R; Pronzato P; Conte PF; Sertoli MR; Amoroso D; Rosso R
    Cancer Treat Rep; 1986 Dec; 70(12):1439-40. PubMed ID: 3466694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of oral idarubicin in metastatic melanoma.
    Martoni A; Pacciarini MA; Piana E; Pannuti F
    Chemioterapia; 1986 Dec; 5(6):414-5. PubMed ID: 3467876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.